Government of Australia Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Australia (1901)

Organization Overview

First Clinical Trial
2005
NCT00123383
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ACT Health | Army Malaria Institute, Australia | Australian Defence Force Malaria and Infectious Disease Institute | Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI) | Australian Government | Australian Government Department of Health | Australian Government Department of Health and Ageing | Department of Health, Victorian Government | Government of Western Australia, Department of Health | Griffith Base Hospital | National Health and Medical Research Council, Clinical Trials Centre | National Health & Medical Research Council of Australia (NH&MRC)

Active Ingredients

Drugs in Phase 4 Trials (1)

tafenoquine succinate (arakoda) (1 trial)

Drugs in Phase 3 Trials (20)

amikacin (Amikin) (1 trial)

azithromycin (zithromax) (1 trial)

bedaquiline (sirturo) (1 trial)

cefoxitin (mefoxin) (1 trial)

clarithromycin (biaxin) (1 trial)

clofazimine (lamprene) (1 trial)

doxycycline (vibramycin) (1 trial)

emtricitabine (emtriva) (1 trial)

ethambutol (myambutol) (1 trial)

imipenem (primaxin) (1 trial)

lidocaine (xylocaine) (1 trial)

linezolid (zyvox) (1 trial)

moxifloxacin (avelox) (1 trial)

propofol (diprivan) (1 trial)

rifabutin (mycobutin) (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tenofovir (viread) (1 trial)

tigecycline (tygacil) (1 trial)

Drugs in Phase 2 Trials (19)

177lu-psma-r2 (1 trial)

aprepitant (Emend) (1 trial)

artefenomel (1 trial)

capecitabine (xeloda) (1 trial)

cyanocobalamin (berocca) (1 trial)

dexamethasone (1 trial)

enzalutamide (xtandi) (1 trial)

Filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (1 trial)

folic acid (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

modafinil (provigil) (2 trials)

nicotine (nicorette) (1 trial)

ondansetron (zofran) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (2 trials)

primaquine (1 trial)

Drugs in Phase 1 Trials (2)

phenelzine (nardil) (1 trial)

piperaquine (1 trial)

Drugs in Other Trials (4)

borage (1 trial)

fish oil (Omegavan) (1 trial)

icosapent ethyl (vascepa) (1 trial)

linseed oil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amphetamine-Related Disorders (Phase 2)

Behavior, Addictive (Phase 2)

Breast Neoplasms (Phase 1)

Cocaine-Related Disorders (Phase 2)

Colonic Neoplasms (Phase 3)

Delayed Graft Function (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Lung Diseases (Phase 3)

Malaria (Phase 2)

Mental Disorders (Phase 2)

Mycobacterium Infections (Phase 3)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Psychotic Disorders (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 46